Micosis fungoide e inhibidores del TNFα: ¿riesgo o beneficio?
The growing use of anti-TNF drugs during the last years has reopened the discussion about the possible increased risk of developing non-Hodgkin lymphoma in patients with such type of treatments. We present our clinical experience and critical opinion about the current situation of such issue regarding cutaneous T-cell lymphomas.El creciente uso de fármacos anti-TNF durante los últimos años ha reabierto el debate sobre el posible aumento de riesgo de linfomas no Hodgkin en los pacientes con este tipo de tratamientos. Presentamos nuestra experiencia clínica y opinión critica sobre la situación actual de este tema en relación a los linfomas cutáneos de células T.
Department of Dermatology, Hospital 12 de Octubre, Avenida de Córdoba S/N, 28041, Madrid. lydia.maroasjimenez@gmail.com.
Lidia
L
Maroñas-Jiménez
Sara
S
Burillo-Martínez
Fátima
F
Tous-Romero
Jose Luis
JL
Rodríguez-Peralto
Javier
J
Ortiz de Frutos
Pablo Luis
PL
Ortiz-Romero
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000139:chemically induced* / Q000473:pathology; D018570:Risk Assessment; D012307:Risk Factors; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept